Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs 675

Quick answer

Neurology & CNS: NovaPharmaNews indexes 675 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Pipeline programs

Page 7 of 15

  1. Diazepam Buccal Film 12.5 mg

    Aquestive Therapeutics

    Epilepsy

    phase 2 small molecule completed

    1 trial

  2. E2007-G000-236

    Eisai Co.,

    Childhood Epilepsy

    phase 2 small molecule active

    1 trial

  3. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  4. Evaluation of the safety and efficacy of Cont... for Parkinson's disease

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 other active

    1 trial

  5. Everolimus

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  6. ExPlas

    Wuhan Createrna Science and Technology Co., Ltd

    Early symptomatic phase Alzheimer's disease

    phase 2 small molecule active

    1 trial

  7. Exercise Programme

    United Therapeutics Europe Ltd

    Parkinson's Disease

    phase 2 other completed

    1 trial

  8. Flortaucipir, Placebo to match LY3372689

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  9. Fluoxetine

    The First People's Hospital of Lianyungang

    Depression

    phase 2 small molecule active

    1 trial

  10. GH001-TRD-201

    Elan Pharma International

    Treatment-resistant depression (TRD)

    phase 2 small molecule active

    1 trial

  11. GN-002

    Sana Biotechnology

    Parkinson’s Disease

    phase 2 small molecule active

    1 trial

  12. GN43271

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 2 other active

    1 trial

  13. GSK4527226

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  14. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  15. GWP42003-P 5 mg/kg/day Dose

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  16. GWP42006

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    2 trials

  17. Glatiramer Acetate, N-Acetylcysteine

    Teva Pharma GmbH

    Relapse Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  18. GlyT-1 inhibitor-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  19. Green Tea Polyphenols (EGCG/ECG)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  20. I5T-MC-AACI

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  21. IC 2019-02

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  22. IM045-1018

    Celgene Europe Limited

    Multiple Sclerosis Spasticity

    phase 2 small molecule active

    1 trial

  23. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Parkinson Disease Psychosis

    phase 2 small molecule terminated

    1 trial

  24. Iloperidone crystalline formulation

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  25. Insulin

    United Therapeutics Europe Ltd

    Multiple Sclerosis, Relapsing-Remitting

    phase 2 small molecule completed

    1 trial

  26. K0706

    Advanced Accelerator Applications

    Early Parkinson Disease

    phase 2 small molecule terminated

    1 trial

  27. KYV-101

    Kyverna Therapeutics

    Multiple Sclerosis, Primary Progressive

    phase 2 mab active

    1 trial

  28. KYV101-007

    Kyverna Therapeutics

    Primary or Secondary Progressive Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  29. Ketamine Hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  30. LX1001

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 mab completed

    1 trial

  31. LY2140023

    Novo Nordisk A/S

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  32. Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG

    MEDA Pharma GmbH & Co. KG

    Mild Cognitive impairment due to Alzheimer Disease

    phase 2 small molecule active

    1 trial

  33. Laquinimod 0.6

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial

  34. Leuprolide acetate

    Voyager Therapeutics

    Alzheimer Disease

    phase 2 small molecule completed

    2 trials

  35. Low Dose GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  36. Lu AA34893

    H. Lundbeck A/S

    Depression in Patients With Bipolar Disorder

    phase 2 small molecule terminated

    1 trial

  37. Lu AE58054

    H. Lundbeck A/S

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  38. Luvadaxistat

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  39. MINOCIN 100 mg capsule rigide

    Zafatek

    Depression

    phase 2 small molecule active

    1 trial

  40. MK-1167

    Merck KGaA, Darmstadt, Germany

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  41. MK-1167-008

    Merck Sharp and Dohme

    Alzheimer’s disease dementia

    phase 2 small molecule active

    1 trial

  42. MK-2214

    Merck KGaA, Darmstadt, Germany

    Early Alzheimer's Disease

    phase 2 mab active

    1 trial

  43. MK-2214-004

    Merck Sharp and Dohme

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  44. ML-007C-MA

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial

  45. ML-007C-MA

    MapLight Therapeutics

    Psychosis Associated With Alzheimer's Disease

    phase 2 small molecule active

    2 trials

  46. MLC901

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  47. Melperone HCl

    Lundbeck Australia Pty Ltd

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  48. Mifepristone

    CORCEPT THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

675 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.